145 related articles for article (PubMed ID: 18563862)
1. Development of an in vitro cell culture assay system for measuring the activation of a neighbouring gene by the retroviral vector.
Hong Y; Yu SS; Yoon NK; Kang SJ; Lee JT; Kim S; Kim JM; Lee K; Jang JW; Kim S
J Gene Med; 2008 Aug; 10(8):847-54. PubMed ID: 18563862
[TBL] [Abstract][Full Text] [Related]
2. Genetic reshuffling reconstitutes functional expression cassettes in retroviral vectors.
Tabotta W; Klein D; Hohenadl C; Salmons B; Günzburg WH
J Gene Med; 2001; 3(5):418-26. PubMed ID: 11601755
[TBL] [Abstract][Full Text] [Related]
3. Enhancer-deleted retroviral vectors restore high levels of superoxide generation in a mouse model of CGD.
Schwickerath O; Brouns G; Thrasher A; Kinnon C; Roes J; Casimir C
J Gene Med; 2004 Jun; 6(6):603-15. PubMed ID: 15170731
[TBL] [Abstract][Full Text] [Related]
4. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.
Recchia A; Bonini C; Magnani Z; Urbinati F; Sartori D; Muraro S; Tagliafico E; Bondanza A; Stanghellini MT; Bernardi M; Pescarollo A; Ciceri F; Bordignon C; Mavilio F
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1457-62. PubMed ID: 16432223
[TBL] [Abstract][Full Text] [Related]
5. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches.
Brandtner EM; Kodajova P; Hlavaty J; Jandl G; Tabotta W; Salmons B; Günzburg WH; Hohenadl C
J Gene Med; 2008 Feb; 10(2):113-22. PubMed ID: 18076132
[TBL] [Abstract][Full Text] [Related]
6. Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential.
Weber EL; Cannon PM
Hum Gene Ther; 2007 Sep; 18(9):849-60. PubMed ID: 17767401
[TBL] [Abstract][Full Text] [Related]
7. Construction of a retroviral vector production system with the minimum possibility of a homologous recombination.
Yu SS; Han E; Hong Y; Lee JT; Kim S; Kim S
Gene Ther; 2003 Apr; 10(8):706-11. PubMed ID: 12692599
[TBL] [Abstract][Full Text] [Related]
8. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
9. Retargeting of retroviral integration sites for the predictable expression of transgenes and the analysis of cis-acting sequences.
Schübeler D; Maass K; Bode J
Biochemistry; 1998 Aug; 37(34):11907-14. PubMed ID: 9718314
[TBL] [Abstract][Full Text] [Related]
10. Optimization of regulated LTR-mediated expression.
Lorens JB; Jang Y; Rossi AB; Payan DG; Bogenberger JM
Virology; 2000 Jun; 272(1):7-15. PubMed ID: 10873744
[TBL] [Abstract][Full Text] [Related]
11. The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors.
Higashimoto T; Urbinati F; Perumbeti A; Jiang G; Zarzuela A; Chang LJ; Kohn DB; Malik P
Gene Ther; 2007 Sep; 14(17):1298-304. PubMed ID: 17597793
[TBL] [Abstract][Full Text] [Related]
12. Retroviral vectors for the transduction of autoregulated, bidirectional expression cassettes.
Unsinger J; Kröger A; Hauser H; Wirth D
Mol Ther; 2001 Nov; 4(5):484-9. PubMed ID: 11708885
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
Sinn PL; Sauter SL; McCray PB
Gene Ther; 2005 Jul; 12(14):1089-98. PubMed ID: 16003340
[TBL] [Abstract][Full Text] [Related]
14. Novel, high expressing and antibiotic-controlled plasmid vectors designed for use in gene therapy.
Liang X; Hartikka J; Sukhu L; Manthorpe M; Hobart P
Gene Ther; 1996 Apr; 3(4):350-6. PubMed ID: 8732167
[TBL] [Abstract][Full Text] [Related]
15. Stable and strictly controlled expression of LTR-flanked autoregulated expression cassettes upon adenoviral transfer.
Unsinger J; Lindenmaier W; May T; Hauser H; Wirth D
Biochem Biophys Res Commun; 2004 Jul; 319(3):879-87. PubMed ID: 15184065
[TBL] [Abstract][Full Text] [Related]
16. Hybrid retroviral vector with MCK enhancers inserted in LTR for stable and specific expression of human factor IX in skeletal muscle.
Wang JM; Hou J; Qiu XF; Kurachi K; Xue JL
Chin Med J (Engl); 2004 Jun; 117(6):893-8. PubMed ID: 15198894
[TBL] [Abstract][Full Text] [Related]
17. Retroviral hybrid LTR vector strategy: functional analysis of LTR elements and generation of endothelial cell specificity.
Richardson TB; Kaspers J; Porter CD
Gene Ther; 2004 May; 11(9):775-83. PubMed ID: 14999228
[TBL] [Abstract][Full Text] [Related]
18. The transcriptional activity of HERV-I LTR is negatively regulated by its cis-elements and wild type p53 tumor suppressor protein.
Chang NT; Yang WK; Huang HC; Yeh KW; Wu CW
J Biomed Sci; 2007 Mar; 14(2):211-22. PubMed ID: 17151828
[TBL] [Abstract][Full Text] [Related]
19. Insertional mutagenesis and clonal dominance: biological and statistical considerations.
Fehse B; Roeder I
Gene Ther; 2008 Jan; 15(2):143-53. PubMed ID: 17972922
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting the performance of different long terminal repeats in the retroviral vector.
Kim S; Lee K; Kim MD; Kang S; Joo CW; Kim JM; Kim SH; Yu SS; Kim S
Biochem Biophys Res Commun; 2006 May; 343(4):1017-22. PubMed ID: 16574062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
